Path to Clonal Theranostics in Luminal Breast Cancers

Integrating tumor heterogeneity in the drug discovery process is a key challenge to tackle breast cancer resistance. Identifying protein targets for functionally distinct tumor clones is particularly important to tailor therapy to the heterogeneous tumor subpopulations and achieve clonal theranostic...

Descripción completa

Detalles Bibliográficos
Autores principales: Hajjaji, Nawale, Aboulouard, Soulaimane, Cardon, Tristan, Bertin, Delphine, Robin, Yves-Marie, Fournier, Isabelle, Salzet, Michel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8793283/
https://www.ncbi.nlm.nih.gov/pubmed/35096604
http://dx.doi.org/10.3389/fonc.2021.802177

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8793283/
https://www.ncbi.nlm.nih.gov/pubmed/35096604
http://dx.doi.org/10.3389/fonc.2021.802177

Ejemplares similares